GleamWall
中文EN

ELTP ELITE PHARMACEUTICALS INC /NV/

Pharmaceutical Preparations · OTC · SEC CIK 1053369 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.8%
TTM net income YoY333.0%
TTM EPS YoY50.0%
Revenue 3-yr CAGR52.2%
Net income 3-yr CAGR50.1%

Margins

Gross margin43.7%
Operating margin25.3%
Net margin41.6%
FCF margin6.0%
EBITDA margin26.1%

Returns

ROE65.6%
ROA46.1%
ROIC (approx.)52.7%
Asset turnover1.11x

Leverage & solvency

Liabilities / assets15.3%
Debt / equity0.00x
Current ratio6.65x
Interest coverage338.18x

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio37.8%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue$40.08M$32.36M$40.75M$31.59M$36.32M$40.21M$32.00M$14.36M
Cost of revenue$24.09M$18.85M$19.98M$18.64M$22.25M$12.99M$14.70M$8.24M
Gross profit$15.99M$13.51M$20.77M$12.95M$14.07M$27.23M$17.30M$6.12M
R&D expense$1.88M$2.03M$1.64M$1.04M$1.39M$1.67M$2.04M$1.79M
SG&A expense$3.78M$3.55M$7.70M$2.47M$4.03M$3.40M$2.03M$2.72M
Operating income$9.93M$7.53M$10.19M$9.01M$8.21M$21.70M$11.15M$1.10M
Interest expense$26,893$27,170$26,855$27,471$28,237$28,797$29,130$31,089
Pretax income$19.74M$7.72M$20.85M$20.83M$15.69M-$564,214$19.27M-$10.65M
Income tax$2.43M$1.81M$2.39M$2.24M$1.99M$5.32M$2.27M$239,175
Net income$17.32M$5.91M$18.46M$18.59M$13.70M-$5.88M$17.00M-$10.89M
EBITDA$10.31M$7.78M$10.44M$9.28M$8.61M$21.98M$11.44M$1.41M
EPS (basic)0.020.01—0.020.01-0.01—-0.01
EPS (diluted)0.010.01—0.010.01-0.01—-0.01
Weighted avg. shares (diluted)1.12B1.13B—1.14B1.14B1.07B—1.07B
Balance sheet
Cash & equivalents$35.34M$39.42M$29.80M$21.56M$27.08M$22.20M$11.77M$8.74M
Receivables$63.22M$50.44M$59.72M$48.53M$40.87M$36.22M$29.21M$18.45M
Inventory$22.52M$24.20M$21.26M$25.10M$18.16M$19.36M$16.24M$20.16M
Current assets$120.74M$114.49M$112.11M$96.79M$85.79M$77.86M$57.74M$48.05M
PP&E, net$11.20M$10.74M$10.18M$10.04M$10.10M$10.27M$10.33M$9.86M
Intangibles$4.79M$4.79M$4.79M$5.64M$5.64M$5.64M$5.64M$7.24M
Total assets$144.29M$139.67M$138.29M$126.41M$117.25M$111.34M$96.39M$90.76M
Current liabilities$18.15M$30.44M$17.39M$13.19M$10.67M$10.76M$11.84M$14.69M
Total liabilities$22.12M$34.84M$39.41M$46.10M$55.66M$63.66M$42.87M$54.31M
Shareholders' equity$122.17M$104.83M$98.88M$80.31M$61.58M$47.68M$53.52M$36.45M
Shares outstanding1.08B1.08B1.08B1.07B1.07B1.07B1.07B1.07B
Cash flow statement
Operating cash flow-$3.07M$10.07M$9.15M-$5.28M$5.10M$14.78M$3.92M-$1.06M
Capital expenditure$732,184$808,964$398,016$206,072$103,334$218,204$754,110$0
Free cash flow-$3.81M$9.26M$8.75M-$5.48M$5.00M$14.56M$3.16M-$1.06M
Investing cash flow-$732,184-$808,964-$398,016-$206,072-$103,334-$218,204-$754,110$0
Financing cash flow-$266,362-$114,594-$41,522-$33,635-$116,468-$4.13M-$137,044-$193,104
Depreciation & amortization$382,456$252,975$252,077$268,662$394,864$275,413$290,392$313,060
Stock-based compensation$20,307$28,476$29,164$45,096$49,918$52,329$52,329$70,578

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.